Well, if you look at our guidance and if you look at our inventory level on a forward basis, we have beat about eight terms. So it is not out of line with what we expect to produce from next quarter. I think we are being relatively conservative in our guidance and yes, it is a little bit tougher to manage the whole supply chain, when there are, again, it doesn't do you any good to have $149.50 of a $150.00 bill of materials, but if the last $0.50 doesn't show up, you can't ship the product. So what we are going to do with that, there is a little bit more of buffer and a little bit more slack in the chain in terms of how effectively we can manage our investment in inventory. You know, that said, we would expect inventory churn rates to improve a bit in the next quarter or two, but I wouldn't expect any breakthroughs in terms of other inventory turnovers. So, I think you are looking at a combination of a growing revenue profile in forward quarters, combined with a component supply marketplace that is being constrained and difficult to manage it. Here you can see, you know, Amit, with the industrial and instrumentation medical segments, up 14% sequentially and some of the other higher mix parts of our business up sequentially. Those tend to be lower inventory turnover businesses, so that kind of (inaudible) a little bit challenged on the inventory side. All that said, I think we ought to be able to manage back to you know, in eight turns at least, and then over the next three or four quarters, get back to that nine level that we have been targeting.
Amit Daryanani – RBC Capital Markets: Got it. And then just a question on the CapEx line, you know, probably Green Point was running around $550 million to $600 million annual revenues. Can you tell us what sort of revenues can you support for Green Point with the current physical capacity that you have, and what sort of incremental dollars can you add to that capacity with the $70 million uptick in CapEx?